Teva Seeks To Bar FDA Approval Of Risperdal ANDAs
Teva Pharmaceuticals USA Inc. has asked a court to temporarily prohibit federal regulators from approving generic versions of the anti-psychotic drug Risperdal after an appeals court overturned a ruling granting the...To view the full article, register now.
Already a subscriber? Click here to view full article